Aenova Expands Production of Tablets with Highly Potent Oncology Drugs

Contract manufacturer Aenova has put a third, high-performance tablet press including integrated automatic in-process control into operation at its site in Regensburg, Germany, to expand its production capacity of highly potent oncology drugs.

The company said that the expansion was made in order to meet the increasing demand of customers for preparations in the oncological environment with highly potent active ingredients (HPAPIs), such as cytostatics, immunosuppressants or hormone-containing products.

With an investment of around €500,000 and now a total of three identical, automated tablet press lines, Aenova will be able to produce up to 1 million tablets per hour in the field of highly potent oncology drugs.

The tablet presses are connected online with three combination upward dedusters and the automatic in-process control equipment. This enables the weight, dimensions and breaking strength of tablets drawn at defined times to be checked regularly and fully automatically.

The use of automatic online in-process control equipment now enables an uninterrupted, regulation-compliant and quality-assured manufacturing process for the tablets, independent of occupational safety regulations, said Aenova. In the area of highly potent products up to the OEB-5 class, special protection must be guaranteed due to the hazard potential for the production personnel.

Christine Beck, SVP of the Solids Business Unit at the Aenova, said: "The implemented expansions are related to the strategic positioning of the Regensburg site as Center of Excellence HPAPI and Oncology Products within the Aenova Group. For this purpose, an extension building for the so-called HPAPIs (High Potency Active Pharmaceutical Ingredients) is planned to be built until 2022 as well as an expansion of the production capacities for hard capsules for high-potency products.”

In Regensburg, Aenova produces and packages an extensive range of solid, semi-solid and liquid dosage forms.

At Aenova’s site in Regensburg, Germany, the new tablet press for highly...
At Aenova’s site in Regensburg, Germany, the new tablet press for highly potent active ingredients enables flexible high containment production. © Aenova Group

Company

Logo:

Aenova Holding GmbH

Berger Strasse 8-10
82319 Starnberg
Germany

Company contact







Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

most read

Photo
19.03.2025 • News

Arkema Launches Acrylic Acid Purification Project

Arkema has announced the launch of its Carat Project at its Carling site in France. This initiative aims to enhance the capabilities and sustainability of the facility, which specializes in producing acrylic monomers and superabsorbent polymers.

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.